コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ainst IL-5, in children and adolescents with eosinophilic esophagitis.
2 phil counts in children and adolescents with eosinophilic esophagitis.
3 implicated a role for periostin in allergic eosinophilic esophagitis.
4 ost often encountered and well studied EGID, eosinophilic esophagitis.
5 uld be aware of the clinical presentation of eosinophilic esophagitis.
6 knowledge of the evaluation and treatment of eosinophilic esophagitis.
7 l presentation, diagnosis, and management of eosinophilic esophagitis.
8 e role of food allergy in many patients with eosinophilic esophagitis.
9 ticasone propionate (FP) in the treatment of eosinophilic esophagitis.
10 allowed FP in pediatric patients with active eosinophilic esophagitis.
11 aphy is useful but will miss subtle signs of eosinophilic esophagitis.
12 that specifically homes to the esophagus in eosinophilic esophagitis.
13 tions for the clinical care of patients with eosinophilic esophagitis.
14 antly, IL-5-deficient mice were resistant to eosinophilic esophagitis.
15 reflux management may need to be treated for eosinophilic esophagitis.
16 ophageal biopsy specimens from patients with eosinophilic esophagitis.
17 ng asthma, chronic rhinosinusitis (CRS), and eosinophilic esophagitis.
18 without GERD, 18 with achalasia, and 15 with eosinophilic esophagitis.
19 roles of IgE and IgG4 in the development of eosinophilic esophagitis.
20 search contributions in our understanding of eosinophilic esophagitis.
21 nts showed esophageal candidiasis, and 2 had eosinophilic esophagitis.
22 gic inflammatory diseases, including asthma, eosinophilic esophagitis, allergic rhinitis, and atopic
23 ageal biopsy specimens from 11 subjects with eosinophilic esophagitis and 8 without (controls) were a
25 ologies to understand the pathophysiology of eosinophilic esophagitis and development of novel therap
26 y, sera were collected from 15 subjects with eosinophilic esophagitis and from 41 without (controls),
27 gion, rs3806932 (G allele protective against eosinophilic esophagitis) and rs2416257 (A allele associ
31 icant increase in the literature surrounding eosinophilic esophagitis as more than two-thirds of the
32 mbling immune complexes were found in 2 of 5 eosinophilic esophagitis biopsy specimens based on ultra
33 o be able to properly identify patients with eosinophilic esophagitis but also be informed about the
34 biopsy specimens from 21 of 24 patients with eosinophilic esophagitis, but in none of the specimens f
36 Esophagectomy samples from 2 patients with eosinophilic esophagitis contained 180 and 300 IgG4 plas
37 herapy) and 20 controls, stored in the Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, we
44 previously proposed that the pathogenesis of eosinophilic esophagitis (EE) is mediated by an IL-13-dr
48 ate (FP) and dose reduction in patients with eosinophilic esophagitis (EoE) and analyzed esophageal t
50 us removal occur frequently in patients with eosinophilic esophagitis (EoE) and harbor a risk for sev
51 responsive, representing 2 entities known as eosinophilic esophagitis (EoE) and PPI-responsive esopha
52 ruments are needed to assess the activity of eosinophilic esophagitis (EoE) and to provide end points
53 l biopsy tissue from individuals with active eosinophilic esophagitis (EoE) and were present at marke
55 of interleukin (IL)-5 in the pathogenesis of eosinophilic esophagitis (EoE) has been established in a
57 expression and translation, in patients with eosinophilic esophagitis (EoE) has not been explored.
59 with subepithelial fibrosis in subjects with eosinophilic esophagitis (EoE) have not been delineated.
93 ACKGROUND & AIMS: Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label u
97 g studies have observed an increased risk of eosinophilic esophagitis (EoE) mostly among first-degree
102 nality and diagnosis and/or recrudescence of eosinophilic esophagitis (EoE) remains unclear, with som
103 ps most likely to trigger allergies achieves eosinophilic esophagitis (EoE) remission in children, da
105 he mechanical properties of the esophagus in eosinophilic esophagitis (EoE) using the functional lumi
108 toms and histological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remi
109 ng eosinophilic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory d
111 senger RNA in the esophagus of patients with eosinophilic esophagitis (EoE), a recently recognized al
113 rs in the rapid increase in the incidence of eosinophilic esophagitis (EoE), but potential exposures
115 ated with pathological conditions, including eosinophilic esophagitis (EoE), in which basal progenito
116 ical, endoscopic, and histologic features of eosinophilic esophagitis (EoE), review the current diagn
117 iagnosis of an emerging form of esophagitis, eosinophilic esophagitis (EoE), which is currently diagn
118 ntions have been used to treat patients with eosinophilic esophagitis (EoE), yielding varied results.
128 verlap between symptoms of GERD and those of eosinophilic esophagitis, functional dyspepsia, and gast
129 ind, placebo-controlled trial of adults with eosinophilic esophagitis given an antibody against IgE (
130 tes of esophageal tissues from patients with eosinophilic esophagitis had a 45-fold increase in IgG4
133 ing on the pathophysiology, and treatment of eosinophilic esophagitis in both children and adults.
135 se in the number of publications relating to eosinophilic esophagitis in terms of case reports, cohor
136 ile the most commonly involved foods causing eosinophilic esophagitis include milk, eggs, nuts, beef,
137 diography may be useful for obvious signs of eosinophilic esophagitis including rings and strictures.
138 ied cytokines relevant toward development of eosinophilic esophagitis, including interleukin-5 and in
139 al or intragastric allergen does not promote eosinophilic esophagitis, indicating that hypersensitivi
156 to specific foods, indicate that, in adults, eosinophilic esophagitis is IgG4-associated, and not an
163 studies support the role of the allergist in eosinophilic esophagitis management, especially for food
166 ive instrument development phase, the PedsQL Eosinophilic Esophagitis Module is now undergoing multis
167 hods, the content validity of the new PedsQL Eosinophilic Esophagitis Module items was supported in t
170 trial, omalizumab did not reduce symptoms of eosinophilic esophagitis or tissue eosinophil counts com
174 at in patients without GERD or patients with eosinophilic esophagitis; patients with GERD had low MI
175 (1) anaphylactic sensitivity to peanut, (2) eosinophilic esophagitis related to cow's milk, and (3)
177 ented the unique epidemiologic parameters of eosinophilic esophagitis, some of its natural history, a
178 presentation, pathogenesis, and treatment of eosinophilic esophagitis, some of which will be summariz
179 During the last 5 years, the emergence of eosinophilic esophagitis stimulated many case series; th
180 ergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and
182 gitis or nonerosive but pH-abnormal GERD) or eosinophilic esophagitis than in patients without GERD o
185 in oral Ag-induced esophageal eosinophilia, eosinophilic esophagitis was induced by allergen exposur
186 patients with eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses.
187 ve, non-glucocorticoid-treated patients with eosinophilic esophagitis who had 2 consecutive endoscopi
188 ixed esophageal tissues from 2 patients with eosinophilic esophagitis who underwent esophagectomy and
189 s review covers the role of the allergist in eosinophilic esophagitis with a focus on the literature
190 ffective in inducing histologic remission in eosinophilic esophagitis, with a more pronounced effect
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。